Literature DB >> 18218983

Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors.

Heather J Evans-Anderson1, Christina M Alfieri, Katherine E Yutzey.   

Abstract

Cardiomyocytes actively proliferate during embryogenesis and withdraw from the cell cycle during neonatal stages. FOXO (Forkhead O) transcription factors are a direct target of phosphatidylinositol-3 kinase/AKT signaling in skeletal and smooth muscle and regulate expression of the Cip/Kip family of cyclin kinase inhibitors in other cell types; however, the interaction of phosphatidylinositol-3 kinase/AKT signaling, FOXO transcription factors, and cyclin kinase inhibitor expression has not been reported for the developing heart. Here, we show that FOXO1 and FOXO3 are expressed in the developing myocardium concomitant with increased cyclin kinase inhibitor expression from embryonic to neonatal stages. Cell culture studies show that embryonic cardiomyocytes are responsive to insulin-like growth factor 1 stimulation, which results in the induction of the phosphatidylinositol-3 kinase/AKT pathway, cytoplasmic localization of FOXO proteins, and increased myocyte proliferation. Likewise, adenoviral-mediated expression of AKT promotes cardiomyocyte proliferation and cytoplasmic localization of FOXO. In contrast, increased expression of FOXO1 negatively affects myocyte proliferation. In vivo myocyte-specific transgenic expression of FOXO1 during heart development causes embryonic lethality at embryonic day 10.5 because of severe myocardial defects that coincide with premature activation of p21(cip1), p27(kip1), and p57(kip2) and decreased myocyte proliferation. Transgenic expression of dominant negative FOXO1 in cardiomyocytes does not obviously affect heart development at embryonic day 10.5, but results in abnormal morphology of the myocardium by embryonic day 18.5 along with decreased cyclin kinase inhibitor expression and increased myocyte proliferation. These data support FOXO transcription factors as negative regulators of cardiomyocyte proliferation and promoters of neonatal cell cycle withdrawal during heart development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18218983     DOI: 10.1161/CIRCRESAHA.107.163428

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  93 in total

1.  Forkhead factor FoxO1 is essential for placental morphogenesis in the developing embryo.

Authors:  Anwarul Ferdous; Jesse Morris; Mohammad Joynal Abedin; Shandon Collins; James A Richardson; Joseph A Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Forkhead family transcription factor FoxO and neural differentiation.

Authors:  Qiang Wen; Haitao Wang; Peter J Little; Remi Quirion; Wenhua Zheng
Journal:  Neurogenetics       Date:  2012-03-28       Impact factor: 2.660

Review 3.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

4.  Effects of FOXO genotypes on longevity: a biodemographic analysis.

Authors:  Yi Zeng; Lingguo Cheng; Huashuai Chen; Huiqing Cao; Elizabeth R Hauser; Yuzhi Liu; Zhenyu Xiao; Qihua Tan; Xiao-Li Tian; James W Vaupel
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-09-30       Impact factor: 6.053

5.  MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro.

Authors:  Nelsa L Estrella; Amanda L Clark; Cody A Desjardins; Sarah E Nocco; Francisco J Naya
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

6.  Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Authors:  Saurabh Dahiya; Srikanth Givvimani; Shephali Bhatnagar; Natia Qipshidze; Suresh C Tyagi; Ashok Kumar
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

7.  FoxO transcription factors promote autophagy in cardiomyocytes.

Authors:  Arunima Sengupta; Jeffery D Molkentin; Katherine E Yutzey
Journal:  J Biol Chem       Date:  2009-08-19       Impact factor: 5.157

Review 8.  Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

Authors:  Shaodong Guo
Journal:  J Endocrinol       Date:  2014-01-08       Impact factor: 4.286

9.  Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo.

Authors:  Shengnan Wu; Qiulun Lu; Ye Ding; Yin Wu; Yu Qiu; Pei Wang; Xiaoxiang Mao; Kai Huang; Zhonglin Xie; Ming-Hui Zou
Journal:  Circulation       Date:  2019-04-16       Impact factor: 29.690

10.  Increasing Cardiomyocyte Atrogin-1 Reduces Aging-Associated Fibrosis and Regulates Remodeling in Vivo.

Authors:  Roberto Mota; Traci L Parry; Cecelia C Yates; Zhaoyan Qiang; Samuel C Eaton; Jean Marie Mwiza; Deepthi Tulasi; Jonathan C Schisler; Cam Patterson; Tania Zaglia; Marco Sandri; Monte S Willis
Journal:  Am J Pathol       Date:  2018-05-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.